StreetInsider.com News Articles

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Tue, 21 Jul 2026 16:05:00 -0400

CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Tue, 21 Jul 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Tue, 21 Jul 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Tue, 21 Jul 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase

Madrigal Pharmaceuticals (MDGL) PT Raised to $739 at Citizens Before Q2 Results

Fri, 17 Jul 2026 05:02:59 -0400

Citizens analyst Jonathan Wolleben raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $739.00 (from $737.00) while maintaining a Market Outperform rating.

The analyst commented, "We reiterate our Market Outperform rating and raise our risk-adjusted, DCF-derived PT on Madrigal Pharmaceuticals to $739 from $737. MDGL is reporting its 2Q financial results on July 30 at 8 a.m. ET. We lower our 2Q26 Rezdiffra estimate to $354M from $375M to be modestly above consensus of $350M, still representing 14% Q/Q growth. The increase in our PT is primarily a result of slightly lower GTN assumptions (including 37% this year vs. 39%

Madrigal Pharmaceuticals (MDGL) PT Raised to $739 at Citizens Before Q2 Results

Fri, 17 Jul 2026 05:02:59 -0400

Citizens analyst Jonathan Wolleben raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $739.00 (from $737.00) while maintaining a Market Outperform rating.

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Thu, 16 Jul 2026 08:00:00 -0400

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Thu, 16 Jul 2026 08:00:00 -0400

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Thu, 16 Jul 2026 08:00:00 -0400

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Thu, 16 Jul 2026 08:00:00 -0400

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

Madrigal Pharmaceuticals receives three new resmetirom patents

Mon, 13 Jul 2026 08:03:37 -0400

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced that the U.S. Patent and Trademark Office issued three new patents related to resmetirom, the active ingredient in its MASH treatment Rezdiffra.

Two of the patents cover F2/F3 fibrosis indications and will be listed in the FDA's Orange Book. U.S. Patent No. 12,667,575, issued June 30, 2026, covers a weight-threshold step-down dosing method of 60mg or 80mg resmetirom for patients with F2/F3 MASH who are also using a moderate CYP2C8 inhibitor, with protection expected through 2045. U.S. Patent No. 12,661,359, issued June 23, 2026, covers the co-administration of rosuvastatin and resmetirom, limiting the daily rosuvastatin

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Mon, 13 Jul 2026 08:00:00 -0400

Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book
Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c)

CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents.

Bill Sibold, Chief Executive Officer of Madrigal, stated: “Building a robust patent estate is a core

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Mon, 13 Jul 2026 08:00:00 -0400

Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book
Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c)

Bill Sibold, Chief Executive Officer of Madrigal, stated: “Building a robust patent estate is a core

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Mon, 13 Jul 2026 08:00:00 -0400

Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book
Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c)

Bill Sibold, Chief Executive Officer of Madrigal, stated: “Building a robust patent estate is a core

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Mon, 13 Jul 2026 08:00:00 -0400

Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book
Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c)

Bill Sibold, Chief Executive Officer of Madrigal, stated: “Building a robust patent estate is a core

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:05:00 -0400

CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase

Ribo and Madrigal hit first milestone in siRNA MASH drug program

Thu, 02 Jul 2026 03:20:38 -0400

Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB, along with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), announced the achievement of the first candidate drug nomination milestone under their siRNA research partnership, according to a press release dated July 1, 2026.

The milestone relates to a collaborative program targeting metabolic dysfunction-associated steatohepatitis (MASH), a liver disease. Following the nomination, the companies said they plan to immediately begin IND-enabling studies in preparation for future clinical trials.

The partnership covers multiple preclinical assets directed at the liver, with a focus on MASH. No financial terms of the collaboration were disclosed.

Li-Ming Gan, co-CEO

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Wed, 01 Jul 2026 21:19:00 -0400

SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Wed, 01 Jul 2026 21:19:00 -0400

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Wed, 01 Jul 2026 21:19:00 -0400

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Wed, 01 Jul 2026 21:19:00 -0400

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Wed, 01 Jul 2026 21:19:00 -0400